Form 4: NEA 18 Venture Growth Equity Acquires Warrants in NeueHealth, Inc.
SEC Form 4 Filing
NEA 18 Venture Growth Equity, L.P. reports the acquisition of warrants and indirect beneficial ownership in NeueHealth, Inc.
Summary
- NEA 18 Venture Growth Equity, L.P. filed a Form 4 detailing changes in beneficial ownership of NeueHealth, Inc. securities.
- The report indicates the acquisition of 185,595 warrants with an exercise price of $0.01 on October 1, 2024.
- These warrants are exercisable from October 2, 2024, and expire on April 30, 2029.
- The warrants are related to a Warrantholders Agreement and Credit Agreement amendments.
- Following the reported transaction, NEA 18 Venture Growth Equity, L.P. directly holds 556,782 shares of common stock.
- NEA Partners 18 VGE, L.P., NEA 18 VGE GP, LLC, and individual managers of NEA 18 VGE GP indirectly hold these securities but disclaim beneficial ownership to the extent they have no pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects a standard transaction and regulatory filing. The acquisition of warrants is a positive sign, but the filing itself is simply a disclosure requirement.
Positives
- The acquisition of warrants suggests continued investment and confidence in NeueHealth, Inc. by NEA 18 Venture Growth Equity, L.P.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders and significant shareholders, allowing the public to monitor potential shifts in ownership and sentiment.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading activities.
- The acquisition of warrants by venture capital firms is a common practice, often tied to debt financing or strategic investments, similar to investments made by firms such as Sequoia Capital or Andreessen Horowitz in other healthcare companies.
Stakeholder Impact
- The acquisition of warrants could be viewed positively by shareholders as it signals continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| August 4, 2023 | Date of the Credit Agreement between the Issuer and the lenders thereto. |
| October 2, 2023 | Date of Incremental Amendment No. 1 to the Credit Agreement. |
| April 8, 2024 | Date of the Warrantholders Agreement and Incremental Amendment No. 2 to the Credit Agreement. |
| October 1, 2024 | Transaction date for the acquisition of warrants. |
| October 2, 2024 | Date the warrants become exercisable. |
| October 3, 2024 | Date of signature for the Form 4 filing. |
| April 30, 2029 | Expiration date of the warrants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.